

REMARKS


Claims 1, 2, 4, 5 and 14 to 37 are in the application. Claims 3 and 6 to 13 have been cancelled. Claims 1, 4 and 5 have been amended. Claims 14 to 37 have been added. Support for the amendments and the newly added claims lie in the claims as originally filed, in the working examples of the specification, on page 2, lines 10 to 13 and lines 18 to 20, and on page 3, lines 11 to 21 of the specification. No new matter is believed added. Applicants reserve their right to file continuation or divisional application on all cancelled or deleted subject matter.

Applicants thank the Examiner for notification of allowable subject matter. While Applicants do not agree with the Examiner's argument and rejection of the method of use claims herein, in order to advance prosecution on the merits the claims have been cancelled and prosecution will be continued in a divisional application.

However, Applicants have retained the pharmaceutical composition claim, claim 5. It is believed that one of skill in the art would readily be able to determine how to make and use such a composition.

It is believed that all the claims in the application are now in condition for allowance. Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below. If any additional fees or charges are required by this paper the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,



Dara L. Dinner
Attorney for Applicant
Registration No. 33,680

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5017
Facsimile (610) 270-5090